Ewing's sarcoma and primitive neuroectodermal family of tumors Journal Article
| Authors: | Carvajal, R.; Meyers, P. |
| Article Title: | Ewing's sarcoma and primitive neuroectodermal family of tumors |
| Abstract: | Ewing's sarcoma (ES) initially was believed to be of perivascular endothelial origin. The Ewing's sarcoma family of tumors (EFT) includes ES of bone (ESB), extraosseous ES (EES), peripheral primitive neuroectodermal tumor of bone (pPNET), and malignant small-cell tumor of the thoracopulmonary region, or Askin's tumor, all of which are now known to be neoplasms of neuroectodermal origin. The degree of neuronal differentiation has been used for histopathologic subclassification of the EFT as classical ES (ESB or EES), which is characterized by minimal evidence of neural differentiation, and pPNET, which displays evidence of neural differentiation by standard microscopy, electron microscopy, or immunohistochemistry. Because the behavior, prognosis, and treatment appear to be similar for all subsets of EFT, this histopathologic subclassification may not be clinically significant, though some debate remains whether neural differentiation predicts for inferior outcome. © 2005 Elsevier Inc. All rights reserved. |
| Keywords: | bone neoplasms; cancer surgery; acute granulocytic leukemia; busulfan; allogeneic stem cell transplantation; clinical feature; clinical trial; review; cisplatin; doxorubicin; dose response; drug efficacy; bone metastasis; cancer adjuvant therapy; cancer radiotherapy; topotecan; drug megadose; recurrent cancer; brain neoplasms; antineoplastic agent; cancer incidence; gastrointestinal stromal tumor; imatinib; carboplatin; interleukin 2; etoposide; blood toxicity; alkylating agent; cyclophosphamide; melphalan; vincristine; stem cell transplantation; antineoplastic activity; chronic myeloid leukemia; carmustine; ifosfamide; thiotepa; irinotecan; ewing sarcoma; sarcoma; lung metastasis; myelodysplastic syndrome; acute myeloblastic leukemia; dactinomycin; soft tissue sarcoma; forecasting; maximum tolerated dose; acute lymphocytic leukemia; dna topoisomerase inhibitor; recombinant granulocyte colony stimulating factor; anthracycline; sarcoma, ewing's; granulocyte colony stimulating factor; neuroectoderm tumor; rapamycin; clinical trials; hemopoietic growth factor; growth disorder; neuroectodermal tumors, primitive; iatrogenic disease; bone marrow metastasis; antisense oligonucleotide; pathologic fracture |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 19 |
| Issue: | 3 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2005-06-01 |
| Start Page: | 501 |
| End Page: | 525 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2005.03.004 |
| PUBMED: | 15939194 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 42" - "Export Date: 24 October 2012" - "CODEN: HCNAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work